To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Sales GSK Plc’s leading vaccines sank in the third quarter after the British drugmaker was hit by limited access to the shots ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract ...

GSK sales hampered by slump in demand for key vaccine - The drugmaker said sales of Arexvy fell sharply in the third quarter, ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...